Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
Inozyme Pharma, Inc. (INZY)
|
Add to portfolio |
|
|
|
| Price: |
$6.78
| | Metrics |
| OS: |
61.7
|
M
| |
-64
|
% ROE
|
| Market cap: |
$419
|
M
| |
-68
|
% ROIC
|
|
Net cash:
|
$40.8
|
M
| |
$0.66
|
per share
|
|
EV:
|
$378
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($67.0)
|
M
| |
|
|
|
EBIT
|
($67.8)
|
M
| |
|
|
| EPS |
($1.61)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Subramanian Sanjay (SVP, CFO) has filed a Form 4 on Inozyme Pharma, Inc. |
| 09/26/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
SC 13D/A
| Longitude Capital Partners III, LLC reports a 9.9% stake in INOZYME PHARMA, INC. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
SC 13D/A
| Pivotal bioVenture Partners Fund I, L.P. reports a 9.5% stake in Inozyme Pharma, Inc. |
| 08/03/2023 |
4
| Pivotal bioVenture Partners Fund I, L.P. (Director) has filed a Form 4 on Inozyme Pharma, Inc. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 8.1 |
| Revenue growth | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 11.6 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | -3.5 |
| Gross margin | | | | | -43.1% |
| Research and development | 47.8 | 37.7 | 46.5 | 16.2 | |
| General and administrative | 20.8 | 18.9 | 10.5 | 4.6 | 3.5 |
| EBIT | -68.7 | -56.6 | -57.0 | -20.8 | -11.6 |
| EBIT margin | | | | | -143.1% |
| Pre-tax income | -67.1 | -56.6 | -56.4 | -19.7 | -7.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -67.1 | -56.6 | -56.4 | -19.7 | -7.0 |
| Net margin | | | | | -86.0% |
| |
| Diluted EPS | ($1.78) | ($2.40) | ($5.11) | ($16.67) | ($6.63) |
| Shares outstanding (diluted) | 37.8 | 23.6 | 11.0 | 1.2 | 1.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|